ME01901B - Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja - Google Patents

Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja

Info

Publication number
ME01901B
ME01901B MEP-2014-91A MEP9114A ME01901B ME 01901 B ME01901 B ME 01901B ME P9114 A MEP9114 A ME P9114A ME 01901 B ME01901 B ME 01901B
Authority
ME
Montenegro
Prior art keywords
roflumilast
pharmaceutically acceptable
hmg
acceptable salt
coa reductase
Prior art date
Application number
MEP-2014-91A
Other languages
English (en)
Inventor
Stefan-Lutz Wollin
Andrea Wohlsen
Clemens Braun
Degenhard Marx
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME01901B publication Critical patent/ME01901B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (56)

1.Farmaceutska kompozicija koja sadrži farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, količinu inhibitora HMG-CoA reduktaze i najmanje jednu farmaceutski prihvatljivu pomoćnu supstancu, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N- oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so, i pri čemu prva količina i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja.
2.Proizvod kombinacije koji sadrži komponente: (A) količinu PDE4 inhibitora; (B) količinu inhibitora HMGCoA reduktaze; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja i pri čemu svaka od komponenti (A) i (B) je formulisana u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom, i pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, i inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so.
3.Oprema koja sadrži komponente: (A) farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom; (B) farmaceutsku formulaciju koja obuhvata količinu inhibitora HMG-CoA reduktaze, u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, i pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, i inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so.
4.Farmaceutska kompozicija prema zahtevu 1, pri čemu PDE4 inhibitor je ROFLUMILAST.
5.Farmaceutska kompozicija prema zahtevu 1, pri čemu PDE4 inhibitor je ROFLUMILAST- N-oksid.
6.Farmaceutska kompozicija prema bilo kom od zahteva 1,4 ili 5, pri čemu inhibiot HMG- CoA reduktaze je SIMVASTATIN.
7. Proizvod kombinacije prema zahtevu 2, pri čemu PDE4 inhibitor je ROFLUMILAST.
8. Proizvod kombinacije prema zahtevu 2, pri čemu PDE4 inhibitor je ROFLUMILAST-N- oksid.
9.Proizvod kombinacije prema bilo kom od zahteva 2, 7 i 8, pri čemu inhibitor HMG-CoA reduktaze je SIMVASTATIN.
10. Oprema prema zahtevu 3, pri čemu PDE4 inhibitor je ROFLUMILAST.
11. Oprema prema zahtevu 3, pri čemu PDE4 inhibitor je ROFLUMILAST-N-oksid.
12.Oprema prema bilo kom od zahteva 3, 10 ili 11, pri čemu inhibitor HMG-CoA reduktaze je SIMVASTATIN.
13.Farmaceutska kompozicija prema bilo kom od zahteva 1,4, 5 ili 6, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
14.Farmaceutska kompozicija prema bilo kom od zahteva 1,4, 5 ili 6, gde je inflamatorno pulmonarno oboljenje COPD.
15.Proizvod kombinacije prema bilo kom od zahteva 2, 7, 8 ili 9, gdeje inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
16.Proizvod kombinacije prema bilo kom od zahteva 2, 7, 8 or 9, gde je inflamatorno pulmonarno oboljenje COPD.
17.Oprema prema bilo kom od zahteva 3, 10, 11 ili 12, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
18.Oprema prema bilo kom od zahteva 3, 10, 11 ili 12, gdeje inflamatorno pulmonarno oboljenje COPD.
19.Primena PDE4 inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli za proizvodnju medikamenta, prvenstveno farmaceutske kompozicije prema pronalasku, za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so.
20.Primena PDE4 inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli za proizvodnju sekvencijalnog ili odvojenog medikamenta za istovremenu primenu, prvenstveno proizvoda kombinacije ili opreme prema pronalasku, za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je SIMVASTATIN ili njegova farmaceutski prihvatljiva so.
21.Primena prema bilo kom od zahteva 19 ili 20, pri čemu PDE4 inhibitor je ROFLUMILAST.
22.Primena prema bilo kom od zahteva 19 ili 20, pri čemu PDE4 inhibitor je ROFLUMILAST-N-oksid.
23.Primena prema bilo kom od zahteva 19, 20, 21 ili 22, pri čemu inhbitor HMG-CoA reduktaze je SIMVASTATIN.
24.Primena prema bilo kom od zahteva 19 do 23, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
25.Primena prema bilo kom od zahteva 19 do 23, gde je inflamatorno pulmonarno oboljenje COPD.
26.Postupak za dobijanje farmaceutske kompozicije kao što je definisano u bilo kom od zahteva 1,4, 5, 6, 13 ili 14, koji obuhvata mešanje PDE4 inhibitora ili njegove farmaceutski prihvatljive soli sa inhibitorom HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli.
27.Farmaceutska kompozicija koja sadrži farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, količinu inhibitora HMG-CoA reduktaze i najmanje jednu farmaceutski prihvatljivu pomoćnu supstancu, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N- oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida, inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutski prihvatljiva so, i pri čemu prva količina i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja.
28.Proizvod kombinacije koji sadrži komponente: (A) količinu PDE4 inhibitora; (B) količinu inhibitora HMGCoA reduktaze; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja i pri čemu svaka od komponenti (A) i (B) je formulisana u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom, i pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutski prihvatljiva so.
29.Oprema koja sadrži komponente: (A) farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom; (B) farmaceutsku formulaciju koja obuhvata količinu inhibitora HMG-CoA reduktaze, u smeši sa najmanje jednom farmaceutski prihvatljivom pomoćnom supstancom; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za prevenciju ili lečenje inflamatornog pulmonarnog obolenja, i pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutski prihvatljiva so.
30.Farmaceutska kompozicija prema zahtevu 27, pri čemu PDE4 inhibitor je ROFLUMILAST.
31.Farmaceutska kompozicija prema zahtevu 27, pri čemu PDE4 inhibitor je ROFLUMILASTN-oxide.
32.Farmaceutska kompozicija prema bilo kom od zahteva 27, 30 ili 31, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN.
33.Farmaceutska kompozicija prema bilo kom od zahteva 27, 30 ili 31, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN hemi-kalcijum seks-hidrat.
34.Proizvod kombinacije prema zahtevu 28, pri čemu PDE4 inhibitor je ROFLUMILAST.
35.Proizvod kombinacije prema zahtevu 28, pri čemu PDE4 inhibitor je ROFLUMILAST-N- oksid.
36.Proizvod kombinacije prema bilo kom od zahteva 28, 34 i 35, pri čemu inhibitor HMG- CoA reduktaze je ATORVASTATIN.
37.Proizvod kombinacije prema bilo kom od zahteva 28, 34 i 35, pri čemu inhibitor HMG- CoA reduktaze je ATORVASTATIN hemi-kalcijum seks-hidrat.
38.Oprema prema zahtevu 29, pri čemu PDE4 inhibitor je ROFLUMILAST.
39.Oprema prema zahtevu 29, pri čemu PDE4 inhibitor je ROFLUMILAST-N-oksid.
40.Oprema prema bilo kom od zahteva 29, 38 ili 39, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN.
41.Oprema prema bilo kom od zahteva 29, 38 ili 39, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN hemikalcijum seks-hidrat.
42.Farmaceutska kompozicija prema bilo kom od zahteva 27, 30, 31, 32 ili 33, gdeje inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
43.Farmaceutska kompozicija prema bilo kom od zahteva 27, 30, 31, 32 ili 33, gde je inflamatorno pulmonarno oboljenje COPD.
44.Proizvod kombinacije prema bilo kom od zahteva 28, 34, 35, 36 ili 37, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
45.Proizvod kombinacije prema bilo kom od zahteva 28, 34, 35, 36 ili 37, gde je inflamatorno pulmonarno oboljenje COPD.
46.Oprema prema bilo kom od zahteva 29, 38, 39, 40 ili 41, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmoname hipertenzije.
47.Oprema prema bilo kom od zahteva 29, 38, 39, 40 ili 41, gde je inflamatorno pulmonarno oboljenje COPD.
48.Primena PDE4 inhibitor ili njegove farmaceutski prihvatljive soli i inhibitora HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli za proizvodnju medikamenta, prvenstveno farmaceutske kompozicije prema pronalasku, za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutska prihvatljiva so.
49.Primena PDE4 inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli za proizvodnju sekvencijalnog ili odvojenog medikamenta za istovremenu primenu, prvenstveno proizvoda kombinacije ili opreme prema pronalasku, za prevenciju ili lečenje inflamatornog pulmonarnog oboljenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILAST-a, farmaceutski prihvatljive soli ROFLUMILAST-a, ROFLUMILAST-N-oksida i farmaceutski prihvatljive soli ROFLUMILAST-N-oksida i inhibitor HMG-CoA reduktaze je ATORVASTATIN ili njegova farmaceutska prihvatljiva so.
50.Primena prema bilo kom od zahteva 48 ili 49, pri čemu PDE4 inhibitor je ROFLUMILAST.
51.Primena prema bilo kom od zahteva 48 ili 49, pri čemu PDE4 inhibitor je ROFLUMILAST-N-oksid.
52.Primena prema bilo kom od zahteva 48, 49, 50 ili 51, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN.
53.Primena prema bilo kom od zahteva 48, 49, 50 ili 51, pri čemu inhibitor HMG-CoA reduktaze je ATORVASTATIN hemi-kalcijum seks-hidrat.
54.Primena prema bilo kom od zahteva 48 do 53, gde je inflamatorno pulmonarno oboljenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
55.Primena prema bilo kom od zahteva 48 do 53, gde je inflamatorno pulmonamo oboljenje COPD.
56.Postupak za dobijanje farmaceutske kompozicije kao što je definisano u bilo kom od zahteva 27, 30, 31,32, 33, 42 ili 43, koji obuhvata mešanje PDE4 inhibitora ili njegove farmaceutski prihvatljive soli sa inhibitorom HMG-CoA reduktaze ili njegove farmaceutski prihvatljive soli.
MEP-2014-91A 2006-07-05 2007-07-03 Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja ME01901B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116625 2006-07-05
EP11164518.0A EP2363130B1 (en) 2006-07-05 2007-07-03 Combination of HMG-CoA reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory pulmonary diseases

Publications (1)

Publication Number Publication Date
ME01901B true ME01901B (me) 2014-12-20

Family

ID=37311957

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2014-91A ME01901B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja
MEP-2014-9A ME01648B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2014-9A ME01648B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja

Country Status (26)

Country Link
US (2) US20100069392A1 (me)
EP (3) EP2363130B1 (me)
JP (3) JP5349302B2 (me)
KR (1) KR101433394B1 (me)
CN (3) CN102772411A (me)
AT (1) ATE535244T1 (me)
AU (1) AU2007271186C1 (me)
BR (1) BRPI0713768A2 (me)
CA (1) CA2656366A1 (me)
CY (2) CY1114742T1 (me)
DK (2) DK2359826T3 (me)
EA (2) EA032476B1 (me)
ES (3) ES2378281T3 (me)
HR (2) HRP20140073T1 (me)
IL (3) IL195433A (me)
ME (2) ME01901B (me)
MX (1) MX2008016123A (me)
NO (1) NO342590B1 (me)
NZ (3) NZ573378A (me)
PL (2) PL2363130T3 (me)
PT (2) PT2359826E (me)
RS (2) RS53084B (me)
SI (2) SI2363130T1 (me)
UA (3) UA106422C2 (me)
WO (1) WO2008003701A2 (me)
ZA (1) ZA200809905B (me)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463084A (zh) * 2008-03-14 2013-12-25 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
DK3152330T3 (da) * 2014-06-05 2021-04-26 Transgenion Int Institute For Regenerative Translational Medicine Gmbh Fremgangsmåde til diagnose af kronisk obstruktiv lungesygdom (KOL), under anvendelse af nye molekylære biomarkører
CA2953209A1 (en) 2014-06-05 2015-12-10 Transgenion-International Institute For Regenerative Translational Medicine Gmbh Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
WO2015185658A2 (en) 2014-06-05 2015-12-10 Medizinische Universität Wien Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021218988A1 (zh) * 2020-04-30 2021-11-04 中国科学院上海药物研究所 Prdx1激动剂及其用途
EP4565302A1 (en) * 2022-08-03 2025-06-11 Chiesi Farmaceutici S.p.A. Dry powder inhaler

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60219A (en) 1979-06-15 1985-05-31 Merck & Co Inc Hypocholesteremic fermentation products of the hmg-coa reductase inhibitor type,their preparation and pharmaceutical compositions containing them
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
WO1984002131A1 (fr) 1982-11-22 1984-06-07 Sandoz Ag Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
PT87929B (pt) 1987-07-10 1995-03-01 Hoechst Ag Processo para a preparacao de derivados de acido 3-desmetil-mevalonico e de composicoes farmaceuticas que os contem
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4863957A (en) 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
FR2642065B1 (fr) 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
ES2245660T3 (es) 1990-11-30 2006-01-16 Otsuka Pharmaceutical Co., Ltd. Derivados de azol y su utilizacion como inhibidores de los radicales superoxidos.
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
NZ251092A (en) 1992-04-02 1996-12-20 Smithkline Beecham Corp 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
ATE200980T1 (de) * 1992-04-02 2001-05-15 Smithkline Beecham Corp Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen
RU2137754C1 (ru) * 1993-07-02 1999-09-20 Бик Гульден Ломберг Хемише Фабрик ГмбХ Фторалкоксизамещенные бензамиды, способ их получения и фармацевтическая композиция на их основе
GB9504460D0 (en) 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
CA2223624C (en) 1995-06-06 2001-02-20 Pfizer Inc. Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
TR200003130T2 (tr) 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
US20010006656A1 (en) 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
DE19944161A1 (de) 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
MY134008A (en) 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
CA2399396A1 (en) 2000-02-10 2001-08-16 Yasuo Sugiyama Tnf- .alpha. inhibitors
JP2001294526A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd ＴＮＦ−α抑制剤
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US20050102317A1 (en) * 2000-07-21 2005-05-12 Ali Kamarei System and method for event calendaring using a customizable rules subset
AU2002210521A1 (en) 2000-09-19 2002-04-02 Novimmune S.A. Use of statins (HMG-CoA reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
KR20030074817A (ko) * 2001-02-15 2003-09-19 알타나 파마 아게 Ｐｄｅ4 억제제로서의 프탈라지논-피페리디노-유도체
MXPA03007960A (es) * 2001-03-06 2003-12-04 Cellegy Pharma Inc Compuestos y metodos para el tratamiento de desordenes urogenitales.
JP4193435B2 (ja) * 2002-07-23 2008-12-10 ブラザー工業株式会社 インクカートリッジ、および、そのインク充填方法
JP4460221B2 (ja) * 2001-05-24 2010-05-12 メルク フロスト カナダ リミテツド １−ビアリール−１，８−ナフチリジン−４−オン系ホスホジエステラーゼ−４阻害薬
CA2450686A1 (en) * 2001-06-27 2003-01-09 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Substituted 8-arylquinoline pde4 inhibitors
US20030114469A1 (en) 2001-09-27 2003-06-19 Cohen David Saul Combinations
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
US20040167199A1 (en) * 2002-11-18 2004-08-26 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
DE60321953D1 (de) * 2002-11-27 2008-08-14 Nycomed Gmbh Neue synergistische zusammensetzung enthaltend roflumilast und formoterol
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
WO2004091626A1 (en) * 2003-04-07 2004-10-28 Osteoscreen, Inc. Bone growth stimulation with no/statin and other no modulating combinations
GEP20084526B (en) 2003-04-11 2008-11-10 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them
CN100441185C (zh) * 2003-04-30 2008-12-10 麦克弗罗斯特加拿大有限公司 8-(3-联芳基)苯基喹啉磷酸二酯酶-4抑制剂
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
JP2006528229A (ja) * 2003-05-22 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト Ｐｄｅ４阻害剤及びｐｄｅ５阻害剤を含有する組成物
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
WO2004110368A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
DE10348646A1 (de) 2003-10-15 2005-05-25 Gkn Driveline International Gmbh Rollbalg mit großem Krümmungsradius
WO2005102348A1 (en) * 2004-04-19 2005-11-03 Loma Linda University Composition and method of decreasing renal ischemic damage
CA2563377A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0415789D0 (en) * 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
DE102004046236A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
GB0508924D0 (en) 2005-04-30 2005-06-08 Astrazeneca Ab New use
GB0510207D0 (en) 2005-05-19 2005-06-22 Astrazeneca Ab Novel combination
PL1894576T3 (pl) 2005-06-08 2011-10-31 Kowa Co Nowy środek do obniżania poziomu triglicerydów
EP1940389A2 (en) * 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
WO2007054896A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CA2664421A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Hmg coa reductase mediated modulation of neurogenesis

Also Published As

Publication number Publication date
CN101484166B (zh) 2012-09-05
JP5349302B2 (ja) 2013-11-20
BRPI0713768A2 (pt) 2012-10-30
EP2363130A1 (en) 2011-09-07
WO2008003701A3 (en) 2008-03-13
CY1114742T1 (el) 2016-12-14
EP2040707A2 (en) 2009-04-01
DK2363130T3 (da) 2014-07-21
CA2656366A1 (en) 2008-01-10
AU2007271186B2 (en) 2013-01-17
ES2443342T3 (es) 2014-02-19
EP2359826B1 (en) 2013-10-30
SI2363130T1 (sl) 2014-09-30
NO342590B1 (no) 2018-06-18
NO20090370L (no) 2009-02-04
EA200900073A1 (ru) 2009-06-30
PT2363130E (pt) 2014-06-25
CN102764440A (zh) 2012-11-07
CN102772411A (zh) 2012-11-14
EP2040707B1 (en) 2011-11-30
UA98466C2 (uk) 2012-05-25
EP2363130B1 (en) 2014-05-07
ES2489265T3 (es) 2014-09-01
UA101556C2 (uk) 2013-04-10
NZ594369A (en) 2013-10-25
CY1115462T1 (el) 2017-01-04
ATE535244T1 (de) 2011-12-15
EP2359826A1 (en) 2011-08-24
JP2013035871A (ja) 2013-02-21
EA021461B1 (ru) 2015-06-30
PL2359826T3 (pl) 2014-04-30
WO2008003701A2 (en) 2008-01-10
IL195433A0 (en) 2009-08-03
RS53084B (sr) 2014-06-30
IL195433A (en) 2013-02-28
HRP20140073T1 (hr) 2014-02-28
JP2013035870A (ja) 2013-02-21
PT2359826E (pt) 2014-01-20
AU2007271186C1 (en) 2013-08-15
CN101484166A (zh) 2009-07-15
NZ573378A (en) 2012-03-30
IL221307A0 (en) 2012-09-24
EA032476B1 (ru) 2019-06-28
MX2008016123A (es) 2009-01-15
US9713614B2 (en) 2017-07-25
ME01648B (me) 2014-09-20
JP2009541459A (ja) 2009-11-26
HRP20140707T1 (hr) 2014-09-12
KR101433394B1 (ko) 2014-08-26
NZ603207A (en) 2013-12-20
PL2363130T3 (pl) 2014-09-30
KR20090025368A (ko) 2009-03-10
SI2359826T1 (sl) 2014-02-28
ES2378281T3 (es) 2012-04-10
UA106422C2 (uk) 2014-08-26
DK2359826T3 (da) 2014-01-20
AU2007271186A1 (en) 2008-01-10
US20150272949A1 (en) 2015-10-01
IL221307A (en) 2014-08-31
IL221309A (en) 2014-12-31
RS53461B (sr) 2014-12-31
ZA200809905B (en) 2009-11-25
US20100069392A1 (en) 2010-03-18
EA201401042A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
ME01901B (me) Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja
HRP20170624T1 (hr) Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008063300A3 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
WO2008011117A3 (en) Antiviral protease inhibitors
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
PH12018502521A1 (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
EA201201496A1 (ru) Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
HRP20110023T1 (hr) Smanjenje prekomjerne težine ili pretilosti
WO2007111983A8 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
TW200718695A (en) Novel piperidine carboxylic acid amide derivatives
WO2007062862A3 (en) Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
EP2323655A4 (en) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT
DE602005022558D1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten
HRP20170267T1 (hr) Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa
WO2008153374A8 (es) Composición farmacéutica que comprende la combinación de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal